Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Current Leases (2019 - 2025)

Abvc Biopharma (ABVC) has disclosed Current Leases for 7 consecutive years, with $317557.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases fell 21.32% year-over-year to $317557.0, compared with a TTM value of $317557.0 through Dec 2025, down 21.32%, and an annual FY2025 reading of $317557.0, down 21.32% over the prior year.
  • Current Leases was $317557.0 for Q4 2025 at Abvc Biopharma, up from $199335.0 in the prior quarter.
  • Across five years, Current Leases topped out at $403581.0 in Q4 2024 and bottomed at $199335.0 in Q3 2025.
  • Average Current Leases over 5 years is $353246.8, with a median of $364605.0 recorded in 2022.
  • The sharpest move saw Current Leases soared 53.56% in 2021, then tumbled 45.46% in 2025.
  • Year by year, Current Leases stood at $347100.0 in 2021, then rose by 6.4% to $369314.0 in 2022, then rose by 8.8% to $401826.0 in 2023, then increased by 0.44% to $403581.0 in 2024, then decreased by 21.32% to $317557.0 in 2025.
  • Business Quant data shows Current Leases for ABVC at $317557.0 in Q4 2025, $199335.0 in Q3 2025, and $282192.0 in Q2 2025.